MedTrace Logo

Switch Maintenance in Pancreatic

NCT05419479 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-02-24

No results posted yet for this study

Summary

This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body.

This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells.

The names of the study drugs involved in this study are:

* Domvanalimab (also known as AB154)
* Zimberelimab (also known as AB122)
* APX005M

Conditions

  • Pancreatic Cancer
  • Adenocarcinoma of the Pancreas
  • Squamous Cell Carcinoma of Pancreas
  • Adenosquamous Carcinoma of the Pancreas

Interventions

DRUG

ZIMBERELIMAB

Via IV on two days per cycle, dosage per protocol

DRUG

DOMVANALIMAB

Via IV on two days per cycle, dosage per protocol

DRUG

APX005M

Via IV on two days per cycle, dosage per protocol

DRUG

FOLFIRI

every two weeks through an infusion at a dose determined by physician

Sponsors & Collaborators

  • Arcus Biosciences, Inc.

    collaborator INDUSTRY

  • Lustgarten Foundation

    collaborator OTHER

  • James Cleary, MD, PhD

    lead OTHER

Principal Investigators

  • James Cleary, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2027-01-31
Completion
2028-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05419479 on ClinicalTrials.gov